Why Is Alpine Immune Sciences Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Alpine Immune Sciences Inc (NASDAQ:ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis at the American Society of Nephrology Kidney Week. The treatment showed clinically meaningful improvements in proteinuria and a significant reduction in disease-related biomarkers. The drug has been well tolerated with no severe infections reported. Following the news, ALPN shares are up 39.35% at $14.66.
November 02, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpine Immune Sciences' stock is trading higher following positive clinical data of povetacicept. The stock is up 39.35%.
The positive clinical data of povetacicept presented by Alpine Immune Sciences has led to a surge in the company's stock price. The drug showed significant improvements in treating autoimmune glomerulonephritis, which has been positively received by the market, leading to a 39.35% increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100